UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic Carcinomas

Breast cancer : basic and clinical research, 2019, Vol.13, p.1178223419842185-1178223419842185

2019

Volltextzugriff (PDF)

Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ

The American journal of pathology, 2019-05, Vol.189 (5), p.946-955

Sanati, Souzan

2019

Volltextzugriff (PDF)

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast

Clinical breast cancer, 2019-04, Vol.19 (2), p.131-136

2019

Volltextzugriff (PDF)

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Nature communications, 2017-03, Vol.8 (1), p.14864-14864, Article 14864

2017

Volltextzugriff (PDF)

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Breast cancer research and treatment, 2021-08, Vol.188 (3), p.615-630

2021

Volltextzugriff (PDF)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Breast cancer research : BCR, 2017-11, Vol.19 (1), p.123-123, Article 123

2017

Volltextzugriff (PDF)

Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study

Head & neck pathology (Totowa, N.J.), 2018-12, Vol.12 (4), p.488-492

2018

Volltextzugriff (PDF)

Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate

Modern pathology, 2009-10, Vol.22 (10), p.1273-1279

2009

Volltextzugriff (PDF)

Correction: Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Nature communications, 2017-04, Vol.8 (1), p.1-1, Article 15479

2017

Volltextzugriff (PDF)

Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer

Annals of surgery, 2016-12, Vol.264 (6), p.1098-1102

2016

Volltextzugriff (PDF)

Abstract P5-13-20: Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-20

2022

Volltextzugriff (PDF)

Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions

Modern pathology, 2016-01, Vol.29 (1), p.25-33

2016

Volltextzugriff (PDF)

The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: a study of 100 cases from four academic institutions

Histopathology, 2016-04, Vol.68 (5), p.713-721

2016

Volltextzugriff (PDF)

Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study

Modern pathology, 2021-12, Vol.34 (12), p.2130-2140

2021

Volltextzugriff (PDF)

Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

Modern pathology, 2020-03, Vol.33 (3), p.354-366

2020

Volltextzugriff (PDF)

Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD9-03-PD9-03

2022

Volltextzugriff (PDF)

Improved laboratory resource utilization and patient care with the use of rapid on‐site evaluation for endobronchial ultrasound fine‐needle aspiration biopsy

Cancer cytopathology, 2013-10, Vol.121 (10), p.544-551

2013

Volltextzugriff (PDF)

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS4-05-GS4-05

2021

Volltextzugriff (PDF)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer

Breast cancer research and treatment, 2017-09, Vol.165 (2), p.355-364

2017

Volltextzugriff (PDF)

Lymphoepithelioma-like carcinoma of the breast: Report of a case mimicking lymphoma

Annals of diagnostic pathology, 2004-10, Vol.8 (5), p.309-315

2004

Volltextzugriff (PDF)

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.504-504

2020

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic Carcinomas

Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study

Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate

Correction: Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer

Abstract P5-13-20: Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples

Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions

The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: a study of 100 cases from four academic institutions

Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study

Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

Improved laboratory resource utilization and patient care with the use of rapid on‐site evaluation for endobronchial ultrasound fine‐needle aspiration biopsy

Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer

Lymphoepithelioma-like carcinoma of the breast: Report of a case mimicking lymphoma

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106

Suchergebnisse filtern